Related Experiment Video
Updated: Mar 12, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening
Christina D Williams1,1, William M Grady1,1, Leah L Zullig1,1
1From Cooperative Studies Program Epidemiology Center-Durham, Durham VA Medical Center, and Division of Medical Oncology, Duke University Medical Center, Durham, North Carolina; Clinical Research Division, Fred Hutchison Cancer Research Center, and Department of Medicine, University of Washington, Seattle, Washington; and Center for Health Services Research in Primary Care, Durham VA Medical Center, and Division of General Internal Medicine, Duke University Medical Center, Durham, North Carolina.
Abstract:
Colorectal cancer (CRC) remains a common cancer and significant public health burden. CRC-related mortality is declining, partly due to the early detection of CRC through robust screening. NCCN has established the NCCN Guidelines for CRC Screening to help healthcare providers make appropriate screening recommendations according to the patient's risk of developing CRC. This review describes the evolution of CRC screening guidelines for average-risk individuals, discusses the role of NCCN Guidelines for CRC Screening in cancer prevention, and comments on the current and emerging use of biomarkers for CRC screening.
